Giovanni Luigi Mancardi

List of Publications by Year
in descending order

397	24,794	8159	9311
papers	citations	76 h-index	143 g-index

404	404	404	22148
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Embracing resilience in multiple sclerosis: a new perspective from COVID-19 pandemic. Psychology, Health and Medicine, 2022, 27, 352-360.	1.3	10
2	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Multiple Sclerosis Journal, 2022, 28, 472-479.	1.4	13
3	Opinion, knowledge, and clinical experience with functional neurological disorders among Italian neurologists: results from an online survey. Journal of Neurology, 2022, 269, 2549-2559.	1.8	8
4	The patientâ€“caregiver dyad: the impact of cognitive and functional impairment. Neurological Sciences, 2022, 43, 2481-2490.	0.9	4
5	Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study. CNS Drugs, 2022, 36, 83-96.	2.7	4
6	Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 2022, 198, 24-45.	1.2	3
7	A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis. Journal of Neurology, 2022, 269, 5337-5346.	1.8	2
8	Prevalence of disability improvement as a potential outcome for multiple sclerosis trials. Multiple Sclerosis Journal, 2021, 27, 706-711.	1.4	6
9	Coverage of the requirements of first and second level stroke unit in Italy. Neurological Sciences, 2021, 42, 1073-1079.	0.9	1
10	Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail. Neurological Sciences, 2021, 42, 9-13.	0.9	43
11	Autologous hematopoietic stem cell transplantation following alemtuzumab therapy in aggressive multiple sclerosis: A report of three cases. Multiple Sclerosis Journal, 2021, 27, 1145-1148.	1.4	4
12	Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. Neurology, 2021, 96, .	1.5	36
13	Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy. Italian Journal of Pediatrics, 2021, 47, 69.	1.0	3
14	Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2103-2107.	1.4	8
15	Hand rehabilitation with sonification techniques in the subacute stage of stroke. Scientific Reports, 2021, 11, 7237.	1.6	10
16	Bone Marrow Transfer in Relapsing-Remitting EAE Ameliorates Disease at First Remission, with No Synergistic Effect upon Co-Transplantation with Mesenchymal Stem Cells. Vaccines, 2021, 9, 736.	2.1	1
17	Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis. Neurotherapeutics, 2021, 18, 2579-2588.	2.1	17
18	Facing epilepsy treatment gap in sub-Saharan Africa. European neurologists increase education and training programs. Journal of the Neurological Sciences, 2021, 429, 117862.	0.3	0

#	Article	IF	Citations
19	Predictors of ocrelizumab effectiveness in patients with multiple sclerosis. Journal of the Neurological Sciences, 2021, 429, 118089.	0.3	1
20	Linking Europe and sub-Saharan Africa in the COVID-19 era. Partnership and teleneurology. Journal of the Neurological Sciences, 2021, 429, 117799.	0.3	0
21	Ecological impact of isolated cognitive relapses in MS. Multiple Sclerosis Journal, 2020, 26, 114-117.	1.4	15
22	Importance of intensive and prolonged rehabilitative treatment on the Guillain-BarrÃ¨ syndrome long-term outcome: a retrospective study. Neurological Sciences, 2020, 41, 321-327.	0.9	18
23	Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplantation, 2020, 55, 283-306.	1.3	128
24	Preserved brain functional plasticity after upper limb taskâ€oriented rehabilitation in progressive multiple sclerosis. European Journal of Neurology, 2020, 27, 77-84.	1.7	12
25	An â€œall-wheel driveâ€•proposal to accelerate clinical research in common and rare neurological diseases. Neurological Sciences, 2020, 41, 789-793.	0.9	0
26	Tailoring B cell depletion therapy in MS according to memory B cell monitoring. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	30
27	COVID-19-related and not related Guillain-BarrÃ© syndromes share the same management pitfalls during lock down: The experience of Liguria region in Italy. Journal of the Neurological Sciences, 2020, 418, 117114.	0.3	24
28	Rehabilitation Before and After Autologous Haematopoietic Stem Cell Transplantation (AHSCT) for Patients With Multiple Sclerosis (MS): Consensus Guidelines and Recommendations for Best Clinical Practice on Behalf of the Autoimmune Diseases Working Party, Nurses Group, and Patient Advocacy Committee of the European Society for Blood and Marrow Transplantation (EBMT). Frontiers in Neurology, 2020, 11, 556141.	1.1	8
29	Aggressive multiple sclerosis: a singleâ€centre, realâ€world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab. European Journal of Neurology, 2020, 27, 2047-2055.	1.7	18
30	Epilepsy in sub-Saharan Africa: is there anything neurologists could learn from HIV/AIDS health care?. Neurological Sciences, 2020, 41, 3341-3343.	0.9	3
31	The Use of Social Media and Digital Devices Among Italian Neurologists. Frontiers in Neurology, 2020, 11, 583.	1.1	18
32	Position Sense Deficits at the Lower Limbs in Early Multiple Sclerosis: Clinical and Neural Correlates. Neurorehabilitation and Neural Repair, 2020, 34, 260-270.	1.4	9
33	Awareness of rare and genetic neurological diseases among italian neurologist. A national survey. Neurological Sciences, 2020, 41, 1567-1570.	0.9	2
34	Listening to the neurological teams for multiple sclerosis: the SMART project. Neurological Sciences, 2020, 41, 2231-2240.	0.9	6
35	123I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies. European Radiology Experimental, 2020, 4, 27.	1.7	2
36	Subclinical motor impairment assessed with an engineered glove correlates with magnetic resonance imaging tissue damage in radiologically isolated syndrome. European Journal of Neurology, 2019, 26, 162-167.	1.7	21

#	Article	IF	Citations
37	The societal impact of treatment with natalizumab of relapsingâ€“remitting multiple sclerosis in Italian clinical practice: The Tysabri^{Â®}PharmacoEconomics (TyPE) Study. Global & Regional Health Technology Assessment, 2019, 2019, 228424031985295.	0.2	0
38	Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod. Journal of the Neurological Sciences, 2019, 405, 116423.	0.3	6
39	Upper limb motor training based on task-oriented exercises induces functional brain reorganization in patients with multiple sclerosis. Neuroscience, 2019, 410, 150-159.	1.1	18
40	Different MRI patterns in MS worsening after stopping fingolimod. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e566.	3.1	18
41	Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study. Neurological Sciences, 2019, 40, 1383-1391.	0.9	11
42	How much do periventricular lesions assist in distinguishing migraine with aura from CIS?. Neurology, 2019, 92, e1739-e1744.	1.5	15
43	CSF oligoclonal bands and normal appearing white matter periventricular damage in patients with clinically isolated syndrome suggestive of MS. Multiple Sclerosis and Related Disorders, 2019, 31, 93-96.	0.9	10
44	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Annals of Neurology, 2019, 85, 470-481.	2.8	118
45	Diagnostic Value of Sural Nerve Biopsy: Retrospective Analysis of Clinical Cases From 1981 to 2017. Frontiers in Neurology, 2019, 10, 1218.	1.1	12
46	Increased incidence of axonal Guillainâ€BarrÃ© syndrome in La Spezia area of Italy: A 13â€year followâ€up study. Journal of the Peripheral Nervous System, 2019, 24, 80-86.	1.4	14
47	Management of acute ischemic stroke, thrombolysis rate, and predictors of clinical outcome. Neurological Sciences, 2019, 40, 319-326.	0.9	24
48	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Multiple Sclerosis Journal, 2019, 25, 591-600.	1.4	13
49	E200k Familial Creutzfeldt-Jakob Disease Presenting with Subacute Multiple Cranial Neuropathy. The Open Neurology Journal, 2019, 13, 72-75.	0.4	1
50	BEAM Vs Cyclophosphamide-Based Conditioning Regimen in Aggressive Multiple Sclerosis: A Retrospective Analysis of European Blood and Marrow Transplantation Society. Blood, 2019, 134, 3313-3313.	0.6	1
51	Neural correlates of lower limbs proprioception: An fMRI study of foot position matching. Human Brain Mapping, 2018, 39, 1929-1944.	1.9	31
52	Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation. Multiple Sclerosis Journal, 2018, 24, 1133-1137.	1.4	32
53	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	3.8	517
54	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2018, 17, 405-415.	4.9	238

#	Article	IF	Citations
55	Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS. Multiple Sclerosis Journal, 2018, 24, 623-631.	1.4	8
56	Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 245-255.	1.4	42
57	Cord cross-sectional area at foramen magnum as a correlate of disability in amyotrophic lateral sclerosis. European Radiology Experimental, 2018, 2, 13.	1.7	3
58	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. Journal of Neurology, 2018, 265, 2851-2860.	1.8	43
59	Brain Stroke Imaging by Means of Microwave Tomography: Quantitative Inversion Procedure, Configuration Set Up, and Preliminary Experimental Results. , 2018, , .		0
60	A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1765-1788.	0.9	7
61	Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report. Multiple Sclerosis and Related Disorders, 2018, 26, 52-54.	0.9	9
62	N-methyl-d-aspartate receptor antibody-related pathologies and pre-existent mental state disorders. Schizophrenia Research, 2018, 202, 406-407.	1.1	1
63	Remarkable Rituximab Response on Tremor Related to Acuteâ€Onset Chronic Inflammatory Demyelinating Polyradiculoneuropathy in an Antineurofascin155 Immunoglobulin G4â€“Seropositive Patient. Movement Disorders Clinical Practice, 2018, 5, 559-560.	0.8	8
64	Interplay between spinal cord and cerebral cortex metabolism in amyotrophic lateral sclerosis. Brain, 2018, 141, 2272-2279.	3.7	33
65	National Institutes of Health Stroke Scale in patients with primary intracerebral hemorrhage. Neurological Sciences, 2018, 39, 1751-1755.	0.9	38
66	A novel prion protein geneâ€truncating mutation causing autonomic neuropathy and diarrhea. European Journal of Neurology, 2018, 25, e91-e92.	1.7	8
67	Subcutaneous Immunoglobulins are a Valuable Treatment Option in Myasthenia Gravis. Journal of		

#	Article	IF	Citations
73	Autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurology, 2017, 88, 2115-2122.	1.5	134
74	Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nature Reviews Neurology, 2017, 13, 391-405.	4.9	207
75	Autologous hematopoietic stem cell transplantation for pediatric multiple sclerosis: a registry-based study of the Autoimmune Diseases Working Party (ADWP) and Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2017, 52, 1133-1137.	1.3	18
76	In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma. Immunology Letters, 2017, 181, 109-115.	1.1	16
77	Teriflunomide treatment reduces B cells in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e403.	3.1	28
78	Inflammatory responses in Multiple Sclerosis normal-appearing white matter and in non-immune mediated neurological conditions with wallerian axonal degeneration: A comparative study. Journal of Neuroimmunology, 2017, 312, 49-58.	1.1	4
79	Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies. Scientific Reports, 2017, 7, 7831.	1.6	27
80	Dramatic rebounds of MS during pregnancy following fingolimod withdrawal. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e377.	3.1	46
81	Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. Neurological Sciences, 2017, 38, 53-59.	0.9	25
82	Motor Imagery as a Function of Disease Severity in Multiple Sclerosis: An fMRI Study. Frontiers in Human Neuroscience, 2017, 11, 628.	1.0	14
83	Clinical epidemiology of amyotrophic lateral sclerosis in Liguria, Italy: An update of LIGALS register. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 535-542.	1.1	29
84	Restingâ€state functional connectivity and motor imagery brain activation. Human Brain Mapping, 2016, 37, 3847-3857.	1.9	32
85	Dysimmune mononeuropathies: A diagnosis not to be missed. Muscle and Nerve, 2016, 54, 1145-1146.	1.0	2
86	TBK1 is associated with ALS and ALS-FTD in Sardinian patients. Neurobiology of Aging, 2016, 43, 180.e1-180.e5.	1.5	40
87	Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20Âyears of experience. Neurological Sciences, 2016, 37, 857-865.	0.9	34
88	Screening, diagnosis, and management of obstructive sleep apnea in dangerous-goods truck drivers: to be aware or not?. Sleep Medicine, 2016, 25, 98-104.	0.8	25
89	Intraspinal stem cell transplantation for amyotrophic lateral sclerosis: Ready for efficacy clinical trials?. Cytotherapy, 2016, 18, 1471-1475.	0.3	21
90	A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2061-2071.	3.3	27

#	Article	IF	Citations
91	Risk of Occupational Accidents in Workers with Obstructive Sleep Apnea: Systematic Review and Meta-analysis. Sleep, 2016, 39, 1211-1218.	0.6	189
92	The heritage of glatiramer acetate and its use in multiple sclerosis. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	14
93	Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis. Journal of Autoimmunity, 2016, 72, 8-18.	3.0	95
94	ATNX2 is not a regulatory gene in Italian amyotrophic lateral sclerosis patients with C9ORF72 GGGGCC expansion. Neurobiology of Aging, 2016, 39, 218.e5-218.e8.	1.5	6
95	An updated Italian normative dataset for the Stroop color word test (SCWT). Neurological Sciences, 2016, 37, 365-372.	0.9	49
96	Alternative Splicing in the HumanPMP22Gene: Implications in CMT1A Neuropathy. Human Mutation, 2016, 37, 98-109.	1.1	10
97	Intraoperative non invasive intracranial pressure monitoring during pneumoperitoneum: a case report and a review of the published cases and case report series. Journal of Clinical Monitoring and Computing, 2016, 30, 527-538.	0.7	13
98	Neural correlates of ankle movements during different motor tasks: A feasibility study. , 2015, 2015, 4679-82.		2
99	Human mesenchymal stem cells target adhesion molecules and receptors involved in T cell extravasation. Stem Cell Research and Therapy, 2015, 6, 245.	2.4	21
100	An engineered glove for investigating the neural correlates of finger movements using functional magnetic resonance imaging. Frontiers in Human Neuroscience, 2015, 9, 503.	1.0	8
101	A normative study of the Italian printed word version of the free and cued selective reminding test. Neurological Sciences, 2015, 36, 1127-1134.	0.9	21
102	Autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurology, 2015, 84, 981-988.	1.5	201
103	Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party. Multiple Sclerosis Journal, 2015, 21, 189-197.	1.4	56
104	Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study. Multiple Sclerosis Journal, 2015, 21, 1423-1430.	1.4	45
105	Economic impact of multiple sclerosis in Italy: focus on rehabilitation costs. Neurological Sciences, 2015, 36, 227-234.	0.9	48
106	Cingulum bundle alterations underlie subjective fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 442-447.	1.4	34
107	HFE p.H63D polymorphism does not influence ALS phenotype and survival. Neurobiology of Aging, 2015, 36, 2906.e7-2906.e11.	1.5	8
108	Dynamic Contrast-Enhanced MRI in the Study of Brain Tumors. Comparison Between the Extended Tofts-Kety Model and a Phenomenological Universalities (PUN) Algorithm. Journal of Digital Imaging, 2015, 28, 748-754.	1.6	3

#	Article	IF	Citations
109	CHCH10 mutations in an Italian cohort of familial and sporadic amyotrophic lateral sclerosis patients. Neurobiology of Aging, 2015, 36, 1767.e3-1767.e6.	1.5	44
110	ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry. Neurobiology of Aging, 2015, 36, 2906.e1-2906.e5.	1.5	19
111	Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathologica, 2015, 130, 279-295.	3.9	160
112	The changing face of multiple sclerosis: Prevalence and incidence in an aging population. Multiple Sclerosis Journal, 2015, 21, 1244-1250.	1.4	53
113	Bilateral motor and premotor cortex hypometabolism in a case of Mills syndrome. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 414-417.	1.1	6
114	A New App for At-Home Cognitive Training: Description and Pilot Testing on Patients with Multiple Sclerosis. JMIR MHealth and UHealth, 2015, 3, e85.	1.8	71
115	Structural correlates of subjective and objective memory performance in multiple sclerosis. Hippocampus, 2014, 24, 436-445.	0.9	23
116	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 845-850.	0.9	66
117	Isolated cognitive relapses in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1035-1037.	0.9	101
118	Acute disseminated encephalomyelitis with severe neurological outcomes following virosomal seasonal influenza vaccine. Human Vaccines and Immunotherapeutics, 2014, 10, 1969-1973.	1.4	9
119	Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMSâ€Trial. Health Expectations, 2014, 17, 36-48.	1.1	12
120	A review of technical aspects of T1-weighted dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in human brain tumors. Physica Medica, 2014, 30, 635-643.	0.4	54
121	Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nature Neuroscience, 2014, 17, 664-666.	7.1	398
122	Genetic counselling in ALS: facts, uncertainties and clinical suggestions. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 478-485.	0.9	99
123	Genetic burden of common variants in progressive and bout-onset multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 802-811.	1.4	11
124	Do NK cells play a role in the possible association between natalizumab treatment and the development of melanoma?. Journal of Neuroimmunology, 2014, 275, 218.	1.1	0
125	Evaluation of IAUGC indices and two DCE-MRI pharmacokinetic parameters assessed by two different theoretical algorithms in patients with brain tumors. Clinical Imaging, 2014, 38, 808-814.	0.8	5
126	Selective impairments of motor sequence learning in multiple sclerosis patients with minimal disability. Brain Research, 2014, 1585, 91-98.	1.1	16

#	Article	IF	Citations
127	Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. BMC Neurology, 2014, 14, 103.	0.8	10
128	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurology, 2014, 14, 114.	0.8	27
129	Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurology, 2014, 14, 65.	0.8	47
130	Upper limb motor rehabilitation impacts white matter microstructure in multiple sclerosis. NeuroImage, 2014, 90, 107-116.	2.1	90
131	Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients. Journal of NeuroImmune Pharmacology, 2013, 8, 1106-1113.	2.1	69
132	The FIG4 gene does not play a major role in causing ALS in Italian patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 228-229.	1.1	8
133	Italian multicentre observational study of the prevalence of CCSVI in multiple sclerosis (CoSMo) Tj ETQq1 1 0.784314 rgBT /Overlock	0.9	16
134	Safe and Effective Outcome of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Aged 90 Years or Older. European Neurology, 2013, 70, 84-87.	0.6	5
135	Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 397-405.	1.1	68
136	Basal ganglia are active during motor performance recovery after a demanding motor task. NeuroImage, 2013, 65, 257-266.	2.1	13
137	Clinical epidemiology of ALS in Liguria, Italy. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 52-57.	1.1	26
138	Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. Multiple Sclerosis Journal, 2013, 19, 1508-1517.	1.4	42
139	Reward responsiveness and fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 233-240.	1.4	41
140	Oxydative phosphorylation in sciatic nerve myelin and its impairment in a model of dysmyelinating peripheral neuropathy. Journal of Neurochemistry, 2013, 126, 82-92.	2.1	16
141	Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption. Multiple Sclerosis Journal, 2013, 19, 1236-1237.	1.4	30
142	The fatigue-motor performance paradox in multiple sclerosis. Scientific Reports, 2013, 3, 2001.	1.6	32
143	Quantitative Assessment of Finger Motor Impairment in Multiple Sclerosis. PLoS ONE, 2013, 8, e65225.	1.1	44
144	Measurement of Blood-Brain Barrier Permeability with T₁-Weighted Dynamic Contrast-Enhanced MRI in Brain Tumors: A Comparative Study with Two Different Algorithms. ISRN Neuroscience, 2013, 2013, 1-6.	1.5	22

#	Article	IF	Citations
145	Autologous Hematopoietic Stem Cell Transplantation In Neuromyelitis Optica: A Retrospective Study Of The EBMT Autoimmune Diseases Working Party In Collaboration With The University Of Sao Paulo, Ribeirao Preto, Brazil. Blood, 2013, 122, 2125-2125.	0.6	3
146	A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Multiple Sclerosis Journal, 2012, 18, 825-834.	1.4	89
147	T137A variant is a pathogenetic SOD1 mutation associated with a slowly progressive ALS phenotype. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 398-399.	2.3	4
148	Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2012, 47, 770-790.	1.3	256
149	Fast course ALS presenting with vocal cord paralysis: Clinical features, bioinformatic and modelling analysis of the novel SOD1 Gly147Ser mutation. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 144-148.	2.3	14
150	C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population. Neurobiology of Aging, 2012, 33, 1848.e15-1848.e20.	1.5	76
151	Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain, 2012, 135, 784-793.	3.7	182
152	Mesenchymal Stem Cells Shape Microglia Effector Functions Through the Release of CX3CL1. Stem Cells, 2012, 30, 2044-2053.	1.4	127
153	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurology, 2012, 12, 124.	0.8	82
154	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurology, 2012, 12, 165.	0.8	78
155	Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. Journal of NeuroImmune Pharmacology, 2012, 7, 665-672.	2.1	29
156	Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Multiple Sclerosis Journal, 2012, 18, 835-842.	1.4	115
157	Gain of glycosylation: A new pathomechanism of myelin protein zero mutations. Annals of Neurology, 2012, 71, 427-431.	2.8	20
158	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurology, The, 2012, 11, 323-330.	4.9	1,039
159	Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 306-308.	0.9	106
160	Impairment in explicit visuomotor sequence learning is related to loss of microstructural integrity of the corpus callosum in multiple sclerosis patients with minimal disability. NeuroImage, 2011, 57, 495-501.	2.1	34
161	FUS mutations in sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2011, 32, 550.e1-550.e4.	1.5	79
162	Mesenchymal Stem Cells for Multiple Sclerosis: Does Neural Differentiation Really Matter?. Current Stem Cell Research and Therapy, 2011, 6, 69-72.	0.6	21

#	Article	IF	Citations
163	Clinical features of Sjogrenâ€™s syndrome in patients with multiple sclerosis. Acta Neurologica Scandinavica, 2011, 124, 109-114.	1.0	18
164	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurology, The, 2011, 10, 520-529.	4.9	204
165	A Novel Hypothesis About Mechanisms Affecting Conduction Velocity of Central Myelinated Fibers. Neurochemical Research, 2011, 36, 1732-1739.	1.6	17
166	Three years of experience: the Italian registry and safety data update. Neurological Sciences, 2011, 31, 295-297.	0.9	28
167	Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. Neurological Sciences, 2011, 32, 181-182.	0.9	31
168	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Groupâ€"Italian Neurological Society. Neurological Sciences, 2011, 32, 351-358.	0.9	17
169	Repeated courses of granulocyte colonyâ€stimulating factor in amyotrophic lateral sclerosis: Clinical and biological results from a prospective multicenter study. Muscle and Nerve, 2011, 43, 189-195.	1.0	64
170	Comments on â€œevidence for acute neurotoxicity after chemotherapyâ€• Annals of Neurology, 2011, 69, 1064-1064.	2.8	0
171	Structural integrity of callosal midbody influences intermanual transfer in a motor reactionâ€time task. Human Brain Mapping, 2011, 32, 218-228.	1.9	49
172	Can we kill an extra bird with the same stone?. Inflammatory Bowel Diseases, 2011, 17, E124-E125.	0.9	1
173	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology, 2011, 77, 1887-1895.	1.5	68
174	Progranulin expression in brain tissue and cerebrospinal fluid levels in multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 1194-1201.	1.4	54
175	B-cell-activating factor in rituximab-treated patients with anti-MAG polyneuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1291-1294.	0.9	17
176	Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology, 2011, 77, 145-150.	1.5	135
177	Primary varicella zoster infection associated with fingolimod treatment. Neurology, 2011, 76, 1023-1024.	1.5	36
178	Autologous Hematopotoietic Stem Cell Transplantation in Multiple Sclerosis with An Intermediate Intensity Conditioning Regimen: The Italian Multi-Centre Experience. Blood, 2011, 118, 334-334.	0.6	0
179	Stem cell transplantation in multiple sclerosis. Current Opinion in Neurology, 2010, 23, 218-225.	1.8	50
180	Frontal networks play a role in fatigue perception in multiple sclerosis.. Behavioral Neuroscience, 2010, 124, 329-336.	0.6	82

#	Article	IF	Citations
181	The spectrum of GNE mutations: allelic heterogeneity for a common phenotype. Neurological Sciences, 2010, 31, 377-380.	0.9	17
182	Loss of epidermal growth factor regulation by cobalamin in multiple sclerosis. Brain Research, 2010, 1333, 64-71.	1.1	19
183	The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. Multiple Sclerosis Journal, 2010, 16, 100-111.	1.4	50
184	Pregnancy and fetal outcomes after interferon-Î² exposure in multiple sclerosis. Neurology, 2010, 75, 1794-1802.	1.5	142
185	Enlarging clinical spectrum of FALS with TARDBP gene mutations: S393L variant in an Italian family showing phenotypic variability and relevance for genetic counselling. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 223-227.	2.3	29
186	Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. Multiple Sclerosis Journal, 2010, 16, 1237-1247.	1.4	27
187	Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. Bone Marrow Transplantation, 2010, 45, 1014-1021.	1.3	42
188	Surrogate endpoints for EDSS worsening in multiple sclerosis. Neurology, 2010, 75, 302-309.	1.5	103
189	Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. Journal of the Neurological Sciences, 2010, 292, 28-35.	0.3	56
190	Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica, 2010, 95, 284-292.	1.7	321
191	Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical Studies. Biology of Blood and Marrow Transplantation, 2010, 16, 1076-1083.	2.0	46
192	Schwann cell-derived factors support serotoninergic neuron survival and promote neurite outgrowth. European Journal of Histochemistry, 2009, 45, 367.	0.6	15
193	A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. Human Molecular Genetics, 2009, 18, 1524-1532.	1.4	106
194	Multiple Sclerosis: Hyperintense Dentate Nucleus on Unenhanced T1-weighted MR Images Is Associated with the Secondary Progressive Subtype. Radiology, 2009, 251, 503-510.	3.6	95
195	Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?. Multiple Sclerosis Journal, 2009, 15, 1043-1047.	1.4	14
196	The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 238-243.	1.4	21
197	Health-related quality-of-life improvements in CIDP with immune globulin IV 10%. Neurology, 2009, 72, 1337-1344.	1.5	57
198	Further data on autologous haemopoietic stem cell transplantation in multiple sclerosis. Lancet Neurology, The, 2009, 8, 219-221.	4.9	5

#	Article	IF	Citations
199	Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A metaâ€analytic approach. Annals of Neurology, 2009, 65, 268-275.	2.8	206
200	The pharmacovigilance program on natalizumab in Italy: 2Âyears of experience. Neurological Sciences, 2009, 30, 163-165.	0.9	16
201	Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks. Neurological Sciences, 2009, 30, 175-177.	0.9	14
202	Retinal nerve fibre layer measurements and optic nerve head analysis in multiple sclerosis patients. Eye, 2009, 23, 407-412.	1.1	21
203	Granulocyte-macrophage colony-stimulating factor activity in cerebrospinal fluid. Acta Neurologica Scandinavica, 2009, 100, 274-277.	1.0	3
204	Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. Journal of Neurochemistry, 2009, 110, 1674-1684.	2.1	169
205	Evidence for aerobic ATP synthesis in isolated myelin vesicles. International Journal of Biochemistry and Cell Biology, 2009, 41, 1581-1591.	1.2	92
206	Magnetic Resonance Imaging in Patients Implanted with Ex-PRESS Stainless Steel Glaucoma Drainage Microdevice. American Journal of Ophthalmology, 2009, 147, 907-911.e1.	1.7	18
207	FP39-WE-05 High incidence of acute leukaemia in multiple sclerosis patients treated with mitoxantrone: a retrospective multicentre Italian study. Journal of the Neurological Sciences, 2009, 285, S120.	0.3	0
208	Detection of motor cortex thinning and corticospinal tract involvement by quantitative MRI in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 47-52.	2.3	80
209	Structural connectivity influences brain activation during PVSAT in Multiple Sclerosis. NeuroImage, 2009, 44, 9-15.	2.1	63
210	Impaired Expression of Ciliary Neurotrophic Factor in Charcot-Marie-Tooth Type 1A Neuropathy. Journal of Neuropathology and Experimental Neurology, 2009, 68, 441-455.	0.9	17
211	Demyelination, Inflammation, and Neurodegeneration in Multiple Sclerosis Deep Gray Matter. Journal of Neuropathology and Experimental Neurology, 2009, 68, 489-502.	0.9	224
212	Supervised automatic procedure to identify new lesions in brain MR longitudinal studies of patients with multiple sclerosis. Radiologia Medica, 2008, 113, 300-306.	4.7	1
213	Carcinoma of the tongue mimicking bulbar amyotrophic lateral sclerosis. Neurological Sciences, 2008, 29, 127-127.	0.9	1
214	Natalizumab: a country-based surveillance program. Neurological Sciences, 2008, 29, 235-237.	0.9	10
215	Introduction. Neurological Sciences, 2008, 29, 347-347.	0.9	5
216	In vitro investigation of poor cerebrospinal fluid suppression on fluid-attenuated inversion recovery images in the presence of a gadolinium-based contrast agent. Magnetic Resonance in Medicine, 2008, 60, 220-223.	1.9	9

#	Article	IF	Citations
217	Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura. Muscle and Nerve, 2008, 38, 1076-1077.	1.0	29
218	Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurology, The, 2008, 7, 626-636.	4.9	197
219	Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurology, The, 2008, 7, 903-914.	4.9	437
220	Involvement of the choroid plexus in multiple sclerosis autoimmune inflammation: A neuropathological study. Journal of Neuroimmunology, 2008, 199, 133-141.	1.1	121
221	Is there a role for mesenchymal stem cells in autoimmune diseases?. Autoimmunity, 2008, 41, 592-595.	1.2	41
222	Callosal Contributions to Simultaneous Bimanual Finger Movements. Journal of Neuroscience, 2008, 28, 3227-3233.	1.7	132
223	LONG-TERM EFFECT OF RITUXIMAB IN ANTI-MAG POLYNEUROPATHY. Neurology, 2008, 71, 1742-1744.	1.5	75
224	Different cellular and molecular mechanisms for early and late-onset myelin protein zero mutations. Human Molecular Genetics, 2008, 17, 1877-1889.	1.4	69
225	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Multiple Sclerosis Journal, 2008, 14, 1225-1233.	1.4	72
226	Autologous hemopoietic stem cell transplantation for multiple sclerosis: Is it worthwile?. Autoimmunity, 2008, 41, 601-610.	1.2	9
227	Multicenter Case-Control Study on Restless Legs Syndrome in Multiple Sclerosis: the REMS Study. Sleep, 2008, 31, 944-952.	0.6	175
228	Autologous Hematopoietic Stem Cell Transplantation (HSCT) for Autoimmune Diseases: 10 Years Experience from the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Diseases. Blood, 2008, 112, 164-164.	0.6	3
229	Relapses After Treatment With Rituximab in a Patient With Multiple Sclerosis and Antiâ€“Myelin-Associated Glycoprotein Polyneuropathy. Archives of Neurology, 2007, 64, 1531.	4.9	30
230	Stem cells for multiple sclerosis: promises and reality. Regenerative Medicine, 2007, 2, 7-9.	0.8	7
231	The incidence and significance of anti-natalizumab antibodies. Neurology, 2007, 69, 1391-1403.	1.5	312
232	Subtle upper limb impairment in asymptomatic multiple sclerosis subjects. Multiple Sclerosis Journal, 2007, 13, 428-432.	1.4	33
233	The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. Multiple Sclerosis Journal, 2007, 13, 1068-1070.	1.4	53
234	Altered Glutamate Reuptake in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis Cortex: Correlation With Microglia Infiltration, Demyelination, and Neuronal and Synaptic Damage. Journal of Neuropathology and Experimental Neurology, 2007, 66, 732-739.	0.9	153

#	Article	IF	Citations
235	Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. Multiple Sclerosis Journal, 2007, 13, 502-508.	1.4	53
236	Neuropathological Advances in Multiple Sclerosis. , 2007, , 3-9.		0
237	Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Annals of Neurology, 2007, 61, 219-227.	2.8	450
238	Predictors of response to rituximab in patients with neuropathy and anti?myelin associated glycoprotein immunoglobulin M. Journal of the Peripheral Nervous System, 2007, 12, 102-107.	1.4	98
239	The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. BMC Genomics, 2007, 8, 65.	1.2	61
240	Autologous Stem Cell Transplantation for Severe Autoimmune Diseases: A 10-Year Experience. Annals of the New York Academy of Sciences, 2007, 1110, 455-464.	1.8	26
241	Human Mesenchymal Stem Cells Promote Survival of T Cells in a Quiescent State. Stem Cells, 2007, 25, 1753-1760.	1.4	231
242	Oxcarbazepine for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. Neurological Sciences, 2007, 28, 156-158.	0.9	31
243	The value of chemical fat-saturation pulse added to T1-weighted spin-echo sequence in evaluating gadolinium-enhancing brain lesions in multiple sclerosis. Radiologia Medica, 2007, 112, 1244-1251.	4.7	4
244	Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and neuroprotection. Expert Opinion on Biological Therapy, 2006, 6, 17-22.	1.4	63
245	A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): The study protocol [EudraCT no.: 2006-000032-27]. Pharmacological Research, 2006, 54, 436-441.	3.1	47
246	Dendritic Cells in Multiple Sclerosis Lesions: Maturation Stage, Myelin Uptake, and Interaction With Proliferating T Cells. Journal of Neuropathology and Experimental Neurology, 2006, 65, 124-141.	0.9	185
247	Axonal damage and demyelination in long-term dorsal root ganglia cultures from a rat model of Charcot-Marie-Tooth typeâ€ƒ1A disease. European Journal of Neuroscience, 2006, 23, 1445-1452.	1.2	21
248	Human mesenchymal stem cells modulate B-cell functions. Blood, 2006, 107, 367-372.	0.6	1,583
249	Symptomatic therapy in multiple sclerosis. Neurological Sciences, 2006, 27, s287-s287.	0.9	0
250	OR.82. Mesenchymal Stem Cells Treat CNS Autoimmunity Through a Dual Effect On Inflammation and Tissue Damage. Clinical Immunology, 2006, 119, S35.	1.4	0
251	Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases. , 2006, 111, 555-566.		30
252	Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain, 2006, 129, 2628-2634.	3.7	122

#	Article	IF	Citations
253	Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2006, 354, 911-923.	13.9	1,249
254	The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNÎ² exposure in multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 578-585.	1.4	27
255	Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Multiple Sclerosis Journal, 2006, 12, 814-823.	1.4	206
256	Prevalence of oedema of the lower limbs in multiple sclerosis patients: a vascular and lymphoscintigraphic study. Multiple Sclerosis Journal, 2006, 12, 659-661.	1.4	10
257	Safety and Tolerability of a â€˜Refrigeration-freeâ€™ Formulation of Interferon Beta-1b - Results of a Double-blind, Multicentre, Comparative Study in Patients with Relapsing-Remitting or Secondary Progressive Multiple Sclerosis. Journal of International Medical Research, 2006, 34, 1-12.	0.4	9
258	Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood, 2005, 105, 2601-2607.	0.6	147
259	Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood, 2005, 106, 1755-1761.	0.6	1,318
260	B-cell differentiation in the CNS of patients with multiple sclerosis. Autoimmunity Reviews, 2005, 4, 549-554.	2.5	54
261	The prevalence of multiple sclerosis in the north?west Italian province of Genoa. Journal of Neurology, 2005, 252, 436-440.	1.8	28
262	Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. Neurological Sciences, 2005, 25, 307-310.	0.9	63
263	Autologous haematopoietic stem cell transplantation. Neurological Sciences, 2005, 26, s19-s19.	0.9	0
264	Neurological research in Italy in 2003 and 2004. Neurological Sciences, 2005, 26, 189-193.	0.9	8
265	Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. Neurological Sciences, 2005, 26, s200-s203.	0.9	17
266	Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 367-371.	1.4	73
267	Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. NeuroImage, 2005, 24, 1139-1146.	2.1	106
268	Experimental Charcotâ€“Marieâ€“Tooth type 1A: A cDNA microarrays analysis. Molecular and Cellular Neurosciences, 2005, 28, 703-714.	1.0	39
269	Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis: A Report of the European Blood and Marrow Transplantation Group (EBMT).. Blood, 2005, 106, 155-155.	0.6	2
270	The prevalence of pain in multiple sclerosis. Neurology, 2004, 63, 919-921.	1.5	274

#	Article	IF	Citations
271	The 14-3-3 protein in multiple sclerosis: a marker of disease severity. Multiple Sclerosis Journal, 2004, 10, 477-481.	1.4	53
272	Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 11064-11069.	3.3	322
273	Expression of ciliary neurotrophic factor (CNTF) in charcot-marie-tooth type 1A (CMT1A) disease. Journal of the Peripheral Nervous System, 2004, 9, 111-111.	1.4	0
274	Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplantation, 2004, 34, 877-881.	1.3	67
275	Î±-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2004, 148, 146-153.	1.1	118
276	Italian version of the Chicago multiscale depression inventory: translation, adaptation and testing in people with multiple sclerosis. Neurological Sciences, 2004, 24, 375-383.	0.9	37
277	Bovine spongiform encephalopathy and Creutzfeldt-Jakob disease: facts and uncertainties underlying the causal link between animal and human diseases. Neurological Sciences, 2004, 25, 122-9.	0.9	24
278	Marburg type and Balï¿½?s concentric sclerosis: rare and acute variants of multiple sclerosis. Neurological Sciences, 2004, 25, s361-s363.	0.9	72
279	Cerebrospinal fluid findings in Devic?s neuromyelitis optica. Neurological Sciences, 2004, 25, s368-s370.	0.9	37
280	Mycophenolate mofetil in dysimmune neuropathies: A preliminary study. Muscle and Nerve, 2004, 29, 748-749.	1.0	51
281	Progressive multifocal leukoencephalopathy in an adult patient with ICF syndrome. Journal of the Neurological Sciences, 2004, 217, 107-110.	0.3	14
282	Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial. Journal of the Neurological Sciences, 2004, 222, 99-104.	0.3	122
283	Corrigendum to â€œComputer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trialâ€•[J. Neurol. Sci. 222 (2004) 99â€“104]. Journal of the Neurological Sciences, 2004, 224, 113.	0.3	1
284	Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease. Experimental Neurology, 2004, 190, 213-223.	2.0	18
285	Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease. Neurobiology of Disease, 2004, 16, 263-273.	2.1	34
286	Safety of the long-time monthly triple dose of a Gd-based contrast agent. European Radiology, 2003, 13, L243-L244.	2.3	5
287	Biological markers of the inflammatory phase of multiple sclerosis. Neurological Sciences, 2003, 24, s271-s274.	0.9	24
288	Cerebellar ataxia: Quantitative assessment and cybernetic interpretation. Human Movement Science, 2003, 22, 189-205.	0.6	35

#	Article	IF	Citations
289	Maintenance of B lymphocyte-related clones in the cerebrospinal fluid of multiple sclerosis patients. European Journal of Immunology, 2003, 33, 3433-3438.	1.6	39
290	Symptomatic medication use in multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 458-460.	1.4	49
291	Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. Journal of Leukocyte Biology, 2003, 73, 584-590.	1.5	159
292	Autoantibodies in Multiple Sclerosis Patients Before and During IFN-Î²1b Treatment: Are They Correlated with the Occurrence of Autoimmune Diseases?. Journal of Interferon and Cytokine Research, 2002, 22, 245-255.	0.5	28
293	Assessment of Normal-Appearing White and Gray Matter in Patients With Primary Progressive Multiple Sclerosis. Archives of Neurology, 2002, 59, 1406-12.	4.9	180
294	Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses. Neurology, 2002, 59, 1429-1432.	1.5	26
295	Hematopoietic stem cell transplantation for multiple sclerosis. Journal of Neurology, 2002, 249, 1088-1097.	1.8	230
296	Neurological research in Europe, as assessed with a four-year overview of neurological science international journals. Journal of Neurology, 2002, 249, 390-395.	1.8	14
297	PHENOTYPE OF PMP22 TRANSGENIC SCHWANN CELLS IN CULTURE. Journal of the Peripheral Nervous System, 2002, 7, 81-81.	1.4	0
298	Growing Region Segmentation Software (GRES) for quantitative magnetic resonance imaging of multiple sclerosis: intra- and inter-observer agreement variability: a comparison with manual contouring method. European Radiology, 2002, 12, 866-871.	2.3	23
299	The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. Journal of Neurology, 2002, 249, 152-163.	1.8	81
300	Demyelination and axonal damage in a non-human primate model of multiple sclerosis. Journal of the Neurological Sciences, 2001, 184, 41-49.	0.3	74
301	The D355V Mutation Decreases EGR2 Binding to an Element within the Cx32 Promoter. Neurobiology of Disease, 2001, 8, 700-706.	2.1	27
302	Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS. Neurology, 2001, 57, 62-68.	1.5	156
303	Tumor-like multiple sclerosis (MS) lesions: neuropathological clues. Neurological Sciences, 2001, 22, S113-S116.	0.9	20
304	Central and peripheral nervous system complications following allogeneic bone marrow transplantation. European Journal of Neurology, 2001, 8, 77-80.	1.7	37
305	Insulin treatment enhances expression of IGF-I in sural nerves of diabetic patients. Muscle and Nerve, 2001, 24, 622-629.	1.0	21
306	PMP22 transgenic dorsal root ganglia cultures show myelin abnormalities similar to those of human CMT1A. Annals of Neurology, 2001, 50, 47-55.	2.8	23

#	Article	IF	Citations
307	Characterization of the response to myelin basic protein in a non human primate model for multiple sclerosis. European Journal of Immunology, 2001, 31, 474-479.	1.6	9
308	Topiramate Relieves Idiopathic and Symptomatic Trigeminal Neuralgia. Journal of Pain and Symptom Management, 2001, 21, 367-368.	0.6	56
309	In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain, 2001, 124, 2540-2549.	3.7	163
310	Liver and thyroid function and autoimmunity during interferon-Î²1b treatment for MS. Neurology, 2001, 57, 1363-1370.	1.5	90
311	Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: how valid is the GABAergic hypothesis?. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 107-110.	0.9	71
312	Leber's hereditary optic neuropathy (LHON/11778) with myoclonus: report of two cases. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 813-816.	0.9	27
313	Magnetic resonance imaging, magnetisation transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain, and cervical cord damage in Leber's hereditary optic neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 444-449.	0.9	68
314	Acute axonal form of Guillain-Barre syndrome in a multiple sclerosis patient: chance association or linked disorders?. European Journal of Neurology, 2000, 7, 223-225.	1.7	35
315	Restricted immune responses lead to CNS demyelination and axonal damage. Journal of Neuroimmunology, 2000, 107, 178-183.	1.1	11
316	Localized lipoatrophy after prolonged treatment with copolymer 1. Journal of Neurology, 2000, 247, 220-221.	1.8	33
317	Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis. Journal of Neurology, 2000, 247, 556-558.	1.8	82
318	The SMile Card: a computerised data card for multiple sclerosis patients. Neurological Sciences, 2000, 21, 93-98.	0.9	4
319	Accumulation of Clonally Related B Lymphocytes in the Cerebrospinal Fluid of Multiple Sclerosis Patients. Journal of Immunology, 2000, 164, 2782-2789.	0.4	234
320	Myelin/Oligodendrocyte Glycoprotein-Induced Autoimmune Encephalomyelitis in Common Marmosets: The Encephalitogenic T Cell Epitope pMOG24â€“36 Is Presented by a Monomorphic MHC Class II Molecule. Journal of Immunology, 2000, 165, 1093-1101.	0.4	123
321	Low-Dose Gabapentin Combined with either Lamotrigine or Carbamazepine Can Be Useful Therapies for Trigeminal Neuralgia in Multiple Sclerosis. European Neurology, 2000, 44, 45-48.	0.6	108
322	An Italian family with Ala-47 transthyretin mutation associated with cardiomyopathy and polyneuropathy. Neuromuscular Disorders, 2000, 10, 52-55.	0.3	6
323	Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Multiple Sclerosis Journal, 2000, 6, 192-193.	1.4	2
324	A patient with multiple sclerosis and Down's syndrome with a rare paroxysmal symptom at onset. European Journal of Neurology, 1999, 6, 505-507.	1.7	12

#	Article	IF	Citations
325	A major influence of the T cell receptor repertoire as compared to antigen processingâ€“presentation in the selection of myelin basic protein epitopes in multiple sclerosis. Journal of Neuroimmunology, 1999, 96, 241-244.	1.1	1
326	Congenital hypomyelination due to myelin protein zero Q215X mutation. Annals of Neurology, 1999, 45, 676-678.	2.8	51
327	Correspondence. Journal of the Neurological Sciences, 1999, 162, 205-207.	0.3	2
328	Multiple sclerosis and non-communicating syringomyelia: a casual association or linked diseases?. Acta Neurologica Scandinavica, 1999, 100, 270-273.	1.0	7
329	Localized Lipoatrophy After Glatiramer Acetate Injection in Patients With Remitting-Relapsing Multiple Sclerosis. Archives of Dermatology, 1999, 135, 1277-1278.	1.7	32
330	Molecular basis of inherited neuropathies. Current Opinion in Neurology, 1999, 12, 603-616.	1.8	24
331	A restricted T cell response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. Clinical and Experimental Immunology, 1998, 111, 186-192.	1.1	18
332	An open-lebel trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology, 1998, 51, 609-611.	1.5	119
333	Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology, 1998, 50, 1127-1133.	1.5	98
334	A Study of Lactoferrin and Antibodies Against Lactoferrin in Neurological Diseases. Advances in Experimental Medicine and Biology, 1998, 443, 301-304.	0.8	1
335	Multifocal motor neuropathy with conduction block after campylobacter jejuni enteritis. Neurology, 1997, 48, 544-544.	1.5	27
336	Underexpression of messenger RNA for peripheral myelin protein 22 in hereditary neuropathy with liability to pressure palsies. Neurology, 1997, 48, 445-449.	1.5	52
337	Soluble HLA Class I and Class II Molecule Levels in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients. Human Immunology, 1997, 54, 54-62.	1.2	32
338	mRNA distribution in adult human brain of GRIN2B, a N-methyl-d-aspartate (NMDA) receptor subunit. Neuroscience Letters, 1997, 239, 49-53.	1.0	43
339	Human herpes virus 6 and human herpes virus 8 DNA sequences in brains of multiple sclerosis patients, normal adults and children. Journal of Neurology, 1997, 244, 450-454.	1.8	93
340	Correlation between PMP-22 messenger mRNA expression and phenotype in hereditary neuropathy with liability to pressure palsies. Annals of Neurology, 1997, 42, 866-872.	2.8	42
341	Differential regulation of the zinc finger genesKrox-20 andKrox-24 (Egr-1) suggests antagonistic roles in Schwann cells. Journal of Neuroscience Research, 1997, 50, 702-712.	1.3	109
342	Differential regulation of the zinc finger genes Krox-20 and Krox-24 (Egr-1) suggests antagonistic roles in Schwann cells. , 1997, 50, 702.		1

#	Article	IF	Citations
343	Use of cosH1 probe in hereditary neuropathy with liability to pressure palsies: A reliable genetic test for demonstration of identical size of 17p11.2 deletion in unrelated patients. Neuroscience Letters, 1996, 213, 71-73.	1.0	0
344	Human Brain Endothelial Cells and Astrocytes Produce ILâ€1Î² but not ILâ€10. Scandinavian Journal of Immunology, 1996, 44, 506-511.	1.3	43
345	Molecular diagnosis of hereditary neuropathy with liability to pressure palsies (HNPP) by detection of 17p11.2 deletion in Italian patients. Journal of Neurology, 1995, 242, 295-298.	1.8	9
346	Molecular analysis of three cases with hereditary motor and sensory neuropathy with myelin outfolding. Neuroscience Letters, 1995, 194, 136-138.	1.0	3
347	Progressive sensory-motor polyneuropathy with tomaculous changes is associated to 17p11.2 deletion. Journal of the Neurological Sciences, 1995, 131, 30-34.	0.3	23
348	Cranial MRI in ataxia-telangiectasia. Neuroradiology, 1995, 37, 77-82.	1.1	52
349	17p11.2 Duplication Is a Common Finding in Sporadic Cases of Charcot-Marie-Tooth Type 1. European Neurology, 1994, 34, 135-139.	0.6	15
350	The POEMS syndrome: Report of six cases. Italian Journal of Neurological Sciences, 1994, 15, 353-358.	0.1	19
351	Intravenous immunoglobulin, plasmalymphocytapheresis and azathioprine in chronic progressive multiple sclerosis. Italian Journal of Neurological Sciences, 1994, 15, 49-53.	0.1	6
352	Peripheral myelin protein-22 expression in charcot-marie-tooth disease type 1a sural nerve biopsies. Journal of Neuroscience Research, 1994, 37, 654-659.	1.3	72
353	Hereditary motor and sensory neuropathy with myelin outfolding: Clinical, genetic and neuropathological study of three cases. Journal of the Neurological Sciences, 1994, 125, 215.	0.3	0
354	Hereditary motor and sensory neuropathy with myelin outfolding: Clinical, genetic and neuropathological study of three cases. Journal of the Neurological Sciences, 1994, 122, 20-27.	0.3	18
355	Expression of common acute lymphoblastic leukemia antigen (CD 10) by myelinated fibers of the peripheral nervous system. Journal of Neuroimmunology, 1993, 45, 61-66.	1.1	6
356	Circulating Lymphocyte Subsets after Total Lymphoid Irradiation in Chronic Progressive Multiple Sclerosis. Annals of the New York Academy of Sciences, 1993, 677, 458-461.	1.8	0
357	Hereditary motor and sensory neuropathy with deafness, mental retardation and absence of large myelinated fibers. Journal of the Neurological Sciences, 1992, 110, 121-130.	0.3	18
358	GFAP expression of human Schwann cells in tissue culture. Brain Research, 1992, 570, 209-217.	1.1	31
359	Schwann cell GFAP expression increases in axonal neuropathies. Journal of the Neurological Sciences, 1991, 102, 177-183.	0.3	24
360	Amyloid beta protein deposition in brains from elderly subjects with leukoaraiosis. Journal of the Neurological Sciences, 1991, 106, 123-127.	0.3	23

#	Article	IF	Citations
361	Ultrastructural localization of beta-amyloid, tau, and ubiquitin epitopes in extracellular neurofibrillary tangles.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 2098-2102.	3.3	92
362	Differential Scanning Calorimetry Characterization of Rabbit Brain Membrane Fractions. International Journal of Neuroscience, 1991, 61, 9-18.	0.8	3
363	Formic acid treatment exposes hidden neurofilament and tau epitopes in abnormal cytoskeletal filaments from patients with progressive supranuclear palsy and Alzheimer's disease. Neuroscience Letters, 1990, 115, 351-355.	1.0	30
364	Neuropathologic Study of Lacunae and Cribriform Cavities of the Brain. European Neurology, 1989, 29, 16-19.	0.6	18
365	A prospective study of acute idiopathic neuropathy II antecedent events.. Journal of Neurology, Neurosurgery and Psychiatry, 1989, 52, 424-425.	0.9	5
366	Unusual neurological manifestations of Lyme disease: A case report. Italian Journal of Neurological Sciences, 1989, 10, 455-456.	0.1	2
367	BORRELIA BURGDORFERI INFECTION AND GUILLAIN-BARRtSYNDROME. Lancet, The, 1989, 334, 985-986.	6.3	14
368	Tau-reactive neurofibrillary tangles in cerebellar cortex from patients with Alzheimer's disease. Neuroscience Letters, 1989, 103, 259-262.	1.0	9
369	Class II antigen expression on human cultured Schwann cells from patients with Charcot-Marie-Tooth disease. Neuroscience Letters, 1989, 100, 331-334.	1.0	9
370	Lacunae and Cribriform Cavities of the Brain. European Neurology, 1988, 28, 11-17.	0.6	38
371	Direct Immunofluorescence in Sural Nerve Biopsies. European Neurology, 1988, 28, 262-269.	0.6	17
372	Cerebrospinal fluid and neuropathological study in Devic's syndrome. Journal of the Neurological Sciences, 1987, 82, 281-290.	0.3	26
373	Zoster sine herpete causing encephalomyelitis. Italian Journal of Neurological Sciences, 1987, 8, 67-70.	0.1	11
374	Eyelid opening disorders. Neuro-Ophthalmology, 1986, 6, 341-346.	0.4	0
375	SCHWANN CELL EXPRESSION OF HLA-DR ANTIGEN IN PERIPHERAL NEUROPATHIES. Lancet, The, 1986, 328, 1282-1283.	6.3	18
376	Italian multicenter study of dementia: a pathologically verified case of Alzheimer disease. Italian Journal of Neurological Sciences, 1986, 7, 161-163.	0.1	0
377	Peripheral neuropathy in Cockayne syndrome. Italian Journal of Neurological Sciences, 1986, 7, 447-452.	0.1	9
378	â€˜Apraxiaâ€™ of eye opening in idiopathic Parkinson's disease. Neurology, 1986, 36, 134-134.	1.5	8

#	Article	IF	Citations
379	A quantitative and ultrastructural study of substantia nigra and nucleus centralis superior in Alzheimer's disease. Acta Neuropathologica, 1985, 68, 218-223.	3.9	67
380	Endothelial Mitochondrial Content of Cerebral Cortical Capillaries in Alzheimerâ€™s Disease. European Neurology, 1985, 24, 49-52.	0.6	8
381	Neural, Pituitary, and Mammary Tumors in Sprague-Dawley Rats Treated with X Irradiation to the Head and N-Ethyl-N-Nitrosourea (ENU) during the Early Postnatal Period: A Statistical Study of Tumor Incidence and Survival. Radiation Research, 1985, 101, 460.	0.7	11
382	Locked-In Syndrome in Acute Inflammatory Polyradiculoneuropathy. European Neurology, 1984, 23, 137-140.	0.6	10
383	Bannwarth syndrome: report of two cases. Italian Journal of Neurological Sciences, 1983, 4, 485-487.	0.1	1
384	Fibrous astrocytes in Alzheimer's disease and senile dementia of Alzheimer's type. Acta Neuropathologica, 1983, 61, 76-80.	3.9	77
385	Solitary intracranial plasmacytoma. Cancer, 1983, 51, 2226-2233.	2.0	74
386	Skin Fibroblasts in Huntingtonâ€™s Disease. European Neurology, 1983, 22, 283-288.	0.6	8
387	Spongiform-like changes in Alzheimer's disease. Acta Neuropathologica, 1982, 56, 146-150.	3.9	17
388	Creutzfeldt-Jakob disease in the city and district of Genoa: estimated mortalityrate in the six year period 1974â€“1979. Italian Journal of Neurological Sciences, 1981, 2, 189-192.	0.1	5
389	Thickening of the basement membrane of cortical capillaries in Alzheimer's disease. Acta Neuropathologica, 1980, 49, 79-83.	3.9	136
390	Loss of Striatal Neurons in Parkinsonâ€™s Disease: a Cytometric Study. European Neurology, 1980, 19, 339-344.	0.6	53
391	Tendency to Periodic Recurrence of EEG Changes in Laforaâ€™s Disease. European Neurology, 1979, 18, 129-135.	0.6	2
392	The fine structure of subcortical neurofibrillary tangles in progressive supranuclear palsy. Acta Neuropathologica, 1979, 45, 147-152.	3.9	64
393	Early myoclonus and quasiperiodic EEG changes in non-familial Alzheimer's disease. Italian Journal of Neurological Sciences, 1979, 1, 181-187.	0.1	1
394	Progressive supranuclear palsy 1979: an overview. Neurological Sciences, 1979, 1, 205-222.	0.9	44
395	Early degeneration of the cerebellar cortex, particularly the granular cells. Journal of Neurology, 1978, 219, 177-183.	1.8	1
396	Nerve Cell Loss with Aging in the Putamen. European Neurology, 1978, 17, 286-291.	0.6	100

#	Article	IF	Citations
397	Primary Immunodeficiency with early Encephalopathy in Two Siblings. European Neurology, 1975, 13, 405-417.	0.6	2